NTLAIntellia Therapeutics
About Intellia Therapeutics
Intellia Therapeutics (NASDAQ:NTLA) is a biotechnology firm engaged in developing groundbreaking therapies using CRISPR/Cas9 technology for gene editing. This innovative approach allows for precise editing of the genome, offering potential treatments for genetic disorders and diseases with unmet medical needs. The company's portfolio includes in vivo programs targeting conditions like Transthyretin amyloidosis (ATTR), a life-threatening disease, and several ex vivo projects focusing on engineering next-generation cell therapies for cancer and other diseases. Intellia's objective is to harness the power of CRISPR/Cas9 to bring curative therapies to patients worldwide, demonstrating a commitment to advancing medical science and improving human health.
What is NTLA known for?
Snapshot
Public US
Ownership
2014
Year founded
623
Employees
Cambridge, United States
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Newton, US
Products and/or services of Intellia Therapeutics
- CRISPR/Cas9 technology for genome editing, aimed at treating genetic diseases by modifying disease-causing genes.
- In vivo therapy for Transthyretin (ATTR) amyloidosis, a progressive condition affecting the heart and nerves.
- Ex vivo cell therapies for cancer, using engineered human cells to target and destroy cancer cells.
- Research on Hemophilia B treatments, focusing on correcting the gene responsible for this blood clotting disorder.
- Development of therapies for Alpha-1 Antitrypsin Deficiency (AATD), a disease that affects the lungs and liver.
- Collaboration on developing CRISPR/Cas9-based therapies for sickle cell disease, aiming to correct the mutated gene causing the disease.
Intellia Therapeutics executive team
- Dr. John M. Leonard M.D.President, CEO & Director
- Mr. Edward J. Dulac IIIExecutive Vice President, Chief Financial Officer and Treasurer
- Mr. Michael P. DubeVP, CAO & Principal Accounting Officer
- Mr. James E. Basta Esq., J.D.Executive VP, General Counsel & Corporate Secretary
- Dr. David Lebwohl M.D.Executive VP & Chief Medical Officer
- Dr. Rachel E. Haurwitz Ph.D.Co-Founder
- Dr. Jennifer A. Doudna Ph.D.Founder & Member of Scientific Advisor Board
- Dr. Derrick J. Rossi Ph.D.Founder & Member of Scientific Advisor Board
- Dr. Rodolphe Barrangou M.B.A., Ph.D.Founder & Member of Scientific Advisor Board
- Prof. Luciano Marraffini Ph.D.Founder & Member of Scientific Advisor Board